DNA

Washington Research Foundation announces 2026 cohort of WRF Postdoctoral Fellows

12 early-career researchers will receive three years of support to carry out projects at the Institute for Systems Biology, University…

11 hours ago

Landmark Study Shows Combination of Castle Biosciences’ DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests…

14 hours ago

Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition…

14 hours ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase…

14 hours ago

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients…

14 hours ago

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),…

14 hours ago

PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution

Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…

1 day ago

PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution

Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…

1 day ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025…

2 days ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025…

2 days ago